

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

**UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA**

__, Individually and on Behalf of All Others
Similarly Situated,

Plaintiff,

v.

VISTAGEN THERAPEUTICS, INC., SHAWN
K. SINGH, and JOSHUA PRINCE,

Defendants.

Civil Action No.: 26-cv-00427

CLASS ACTION

**COMPLAINT FOR VIOLATION
OF THE FEDERAL SECURITIES
LAWS**

DEMAND FOR JURY TRIAL

1 Plaintiff _ (“Plaintiff”), individually and on behalf of all other persons similarly situated,
2 by his undersigned attorneys, alleges in this Complaint for violations of the federal securities
3 laws (the “Complaint”) the following based upon knowledge with respect to his own acts, and
4 upon facts obtained through an investigation conducted by his counsel, which included, inter
5 alia: (a) review and analysis of relevant filings made by Vistagen Therapeutics, Inc.
6 (“Vistagen” or the “Company”) with the United States Securities and Exchange Commission (the
7 “SEC”); (b) review and analysis of Vistagen’s public documents, conference calls, press releases,
8 and stock chart; (c) review and analysis of securities analysts’ reports and advisories concerning
9 the Company; and (d) information readily obtainable on the internet.
10

11 Plaintiff believes that further substantial evidentiary support will exist for the allegations
12 set forth herein after a reasonable opportunity for discovery. Most of the facts supporting the
13 allegations contained herein are known only to the defendants or are exclusively within their
14 control.
15

16 **NATURE OF THE ACTION**

17 1. This is a federal securities class action on behalf of all investors who purchased
18 or otherwise acquired Vistagen common stock between April 1, 2024 and December 16, 2025,
19 inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of
20 the federal securities laws (the “Class”).
21

22 2. Defendants provided investors with material information concerning Vistagen’s
23 plan to develop and commercialize its drug fasedienol, an investigational pherine candidate in
24 development for the acute treatment of social anxiety disorder (SAD). Defendants’ statements
25 included, among other things, Vistagen’s positive assertions of fasedienol’s future trial success
26 based on the prior positive results associated with the PALISADE-2 clinical trial, in addition to
27 notable enhancements and operational changes made to the execution of the PALISADE-3
28

1 clinical trial supported a strong likelihood of Phase 3 success and positioned it as a confirmatory
2 study.

3
4 3. Defendants provided these overwhelmingly positive statements to investors while
5 at the same time, disseminating false and misleading statements and/or concealing material
6 adverse facts concerning its Phase 3 PALISADE-3 trial study of fasedienol. This caused Plaintiff
7 and other shareholders to purchase Vistagen's common stock at artificially inflated prices.

8
9 4. The truth began to emerge on December 17, 2025, when Vistagen issued a press
10 release announcing that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute
11 treatment of social anxiety disorder did not demonstrate a statistically significant improvement
12 on the primary endpoint of change on the Subjective Units of Distress Scale (SUDS). In pertinent
13 part, Defendants announced the trial did not achieve its primary endpoint and there was no
14 treatment difference between fasedienol and placebo for the secondary endpoints.

15
16 5. Investors and analysts reacted immediately to Vistagen's revelation. The price of
17 Vistagen's common stock declined dramatically from a closing market of \$4.36 per share on
18 December 16, 2025 to \$0.86 per share on December 17, 2025, a decline of more than 80%.

19
20 **JURISDICTION AND VENUE**

21 6. Plaintiff brings this action, on behalf of himself and other similarly situated
22 investors, to recover losses sustained in connection with Defendants' fraud.

23 7. The claims asserted herein arise under and pursuant to §§10(b) and 20(a) of the
24 Exchange Act (15 U.S.C. §§ 78j(b) and 78t(a)) and Rule 10b-5 promulgated thereunder by the
25 SEC (17 C.F.R. §240.10b-5).

26 8. This Court has jurisdiction over the subject matter of this action pursuant to 28
27 U.S.C. §§1331 and 1337, and Section 27 of the Exchange Act, 15 U.S.C. §78aa.

1 **The Defendants Materially Misled Investors Concerning**
2 **the Viability of Vistagen’s Phase 3 PALISADE-3 Study**

3 *April 1, 2024*

4 20. On April 1, 2024, Vistagen issued a press release announcing enrollment of the
5 first patient in its PALISADE-3 Phase 3 trial of fasedienol, an investigational pherine candidate
6 in development for the acute treatment of social anxiety disorder (SAD). In particular, the press
7 release detailed the study as follows:

8 PALISADE-3, similar to PALISADE-2, is a randomized, double-blind, placebo-
9 controlled Phase 3 study designed to evaluate the efficacy, safety, and tolerability
10 of the acute administration of fasedienol to relieve anxiety symptoms in patients
11 with SAD induced by a public speaking challenge conducted in a clinical setting.
12 The primary outcome measure is the patient self-rated Subjective Units of Distress
13 Scale (SUDS). The U.S. multi-center study is planned to randomize
14 approximately 236 adults ages 18 through 65. Patients will be randomized in a 1:1
ratio to fasedienol or placebo. Patients who complete PALISADE-3 will have an
option to enroll in an open-label extension. Vistagen plans to initiate PALISADE-
4, which will be a replicate of PALISADE-3, during the second half of 2024.

15 21. As part of the press release, Defendant Shawn Singh stated, in relevant part:

16 Initiating PALISADE-3 is another major milestone in our plan to develop and
17 commercialize fasedienol as the first treatment of its kind for social anxiety
18 disorder. We look forward to initiating PALISADE-4 in the second half of this
19 year and advancing our innovative pherine pipeline to deliver pioneering
neuroscience to patients affected by mental health disorders and unsatisfied with
current treatments.

20 *June 11, 2024*

21 22. On June 11, 2024, Vistagen published fiscal year 2024 financial results and
22 corporate update. As part of the press release, Defendant Singh stated, in relevant part:

23 Vistagen’s fiscal 2024 proved to be a year full of remarkable accomplishments.
24 Most notably, with our PALISADE-2 trial of fasedienol, we became the first
25 company to report positive results of a Phase 3 trial for the acute treatment of social
26 anxiety disorder, a mental health disorder affecting the lives of over 30 million
27 adults in the U.S for which there is no FDA-approved acute treatment option. In
28 addition, we recently initiated our PALISADE-3 Phase 3 trial, which, if successful,
has the potential to complement PALISADE-2 in support of a
fasedienol U.S. New Drug Application submission. Our primary focus is on the
high-quality execution of our registration-directed PALISADE Phase 3 program

1 for fasedienol in social anxiety disorder, as well as the further progression of our
2 non-systemic, neurocircuitry-focused pherine development programs involving
3 itruvone for major depressive disorder and hormone-free PH80 for menopausal
4 hot flashes. We are well-positioned on a path toward achieving multiple potential
5 value-creating catalysts during the year ahead as we pursue our mission to develop
6 and commercialize differentiated neuroscience therapies to improve patients' lives
7 worldwide.

8 23. Also as part of the press release, Vistagen provided details of its PALISADE-3
9 Phase 3 trial and corporate updates, in pertinent part:

- 10 • **Initiated PALISADE-3 Phase 3 Trial; Preparation for PALISADE-4
11 Phase 3 Trial Underway.** In the fourth quarter of fiscal 2024, Vistagen
12 launched its PALISADE-3 Phase 3 trial of fasedienol for the acute treatment
13 of SAD. With PALISADE-3 initiated, the Company is now preparing to
14 launch its PALISADE-4 Phase 3 trial in the second half of calendar 2024.
15 PALISADE-3 and PALISADE-4 are designed similarly to PALISADE-2,
16 including an open-label extension for a period of up to 12 months with subjects
17 able to use fasedienol up to 6 times per day in their everyday lives prior to
18 anxiety-provoking social and performance stressors.

19 * * *

- 20 • In the third quarter of fiscal 2024, Vistagen closed an underwritten public
21 offering, providing the Company with cash runway to execute critical
22 milestones in its registration-directed PALISADE Phase 3 program for
23 fasedienol in SAD and across other programs in its neuroscience pipeline.

24 24. During the same day earnings call, Defendant Singh discussed details about the
25 Company's PALISADE-3 trial specifically mentioning "notable enhancements" and "operational
26 changes" to help optimize quality enrollment, stating, in pertinent part:

27 *While the public speaking challenge design of PALISADE-2 and the use of the
28 subjective units of distressed scale, or SUDS, is the primary efficacy end point
in the studies and are unchanged, we've built some notable enhancements into
PALISADE-3 and PALISADE-4 and made some operational changes we
believe will help optimize quality enrollment, enhanced surveillance and control
potential variability as well as drive rigorous protocol adherence through an
execution of PALISADE-3 and PALISADE-4, all against the backdrop of what is
now a far more favorable and stable clinical research environment than at any time
during the pandemic.*

* * *

*We believe success in either PALISADE-3 or PALISADE-4, combined with the
positive results from PALISADE-2 and additional open-label safety data from
all fasedienol clinical trials to be completed next year, may provide substantial*

1 *evidence of fasedienol's effectiveness and safety to support submission of a*
2 *potential U.S. new drug application for the acute treatment of SAD during the*
3 *first half of 2026 which, if approved, could be the first approval of its kind.*

4 *As a reminder, the FDA has granted Fast Track Designation for our*
5 *development of fasedienol for the acute treatment of SAD.*

6 (Emphasis added).

7 25. During the question-and-answer portion of the same day earnings call, Defendant
8 Singh and Defendant Prince elaborated on the PALISADE-3 enrollment cadence compared to
9 prior studies, stating, in pertinent part:

10 <Unknown Analyst> In PALISADE-3, how many patients have you enrolled so
11 far? And is the enrollment cadence looking stronger or slower than the first couple
12 of studies, and then also if you don't mind commenting on the screen failure rate
13 and how that compares to the prior studies as well?

14 <A: Defendant Singh> But what I can tell you is what I emphasized during the
15 prepared remarks, which is *we're very happy with the way that PALISADE-3 has*
16 *kicked off. We've been able to build in some really important efficiencies not*
17 *only throughout the execution of the study, but upfront even, between lead*
18 *generation and actual enrollment through visit 1 and the screening.*

19 *We've been able to achieve a lot of the things that reflect and leverage the lessons*
20 *learned through the course of the prior execution of studies of this particular*
21 *design, leading all the way back to Phase II time.* So I think our team is extremely
22 well positioned to continue this study on track and the same will be the case for
23 PALISADE-4 with the ability to achieve the readouts right around the time that
24 we've guided, which would be mid-'25 and then near the end of '25 for
25 PALISADE-4.

26 * * *

27 <Q: Julian Pino – Stifel, Nicolaus & Co. – Analyst> You described a couple of
28 notable enhancements that you made, things like operational changes, enhanced
surveillance, et cetera. Do you mind just providing a little bit more color on what
exactly you're doing and why that gives you greater confidence as you continue
enrolling PALISADE-3 and soon PALISADE-4?

<A: Defendant Singh> So just to be clear right up front, the public speaking
challenge design will remain the same across PALISADE-2, PALISADE-3 and
PALISADE-4 as well as SUDS is the primary efficacy end point. So no changes
there, those will continue, again, to remain consistent throughout the development
of fasedienol for the acute treatment of SAD. And that's been the case all the way
back to Phase II.

1 Earlier this year, we launched another Phase III trial, PALISADE-3, designed
2 similarly to PALISADE-2 with the objective of replicating the success of that
3 study. Enrollment in the PALISADE-3 study is on track, and we are also on track
4 to initiate our PALISADE-4 Phase III study in the second half of this year, as we
5 previously guided. That study will have the same design as PALISADE-3 and the
6 same objective of replicating the positive results from PALISADE-2. Both of these
7 Phase III studies as well as an exploratory Phase IIa repeat dose study will read
8 out next year.

9 We believe either PALISADE-3 or PALISADE-4, if successful, and together with
10 PALISADE-2, may establish the substantial evidence of the effectiveness of
11 fasedienol in support of a potential U.S. New Drug Application submission to the
12 FDA, which, if approved, could establish fasedienol as the first ever FDA-
13 approved acute treatment of SAD.

14 * * *

15 So again, our U.S. registration-directed PALISADE Phase III program for
16 fasedienol for the acute treatment of SAD is our top priority, and we are on track
17 and well funded to do what's necessary to put us in a position with the potential to
18 achieve that important and very valuable goal for patients and for our stockholders.

19 28. During the question-and-answer portion of the earnings call, Defendants reiterated
20 that the enrollment cadence for PALISADE-3 appeared on track, stating in relevant part:

21 <Q: Lin Tsai – Jefferies LLC – Equity Analyst> So first one for PALISADE-3.
22 Are you by chance seeing higher screen failure rates compared to PALISADE-1
23 and 2? And is there anything else that you might be seeing in real time that gives
24 you that extra boost of confidence you are doing the right thing, enrolling the right
25 patients and executing the study even more rigorously than last time?

26 <A: Defendant Prince> ***I think at this point, what we've seen in terms of screen
27 failure rates in terms of those that have a high enough score in the first public
28 speaking challenge in terms of an anxiety score to move on to the second public
speaking challenge, we've been pleasantly surprised that those rates have come
in consistent with our projections.*** So we're seeing, again, progress of the study
that's in line with expectations towards the targets that we've established. And so
I think in general, really things going as expected there.

29 <Q: Lin Tsai – Jefferies LLC – Equity Analyst> And then can you remind us how
30 long it took for you to start in PALISADE-1 and 2 -- I guess -- maybe PALISADE-
31 1 and whether the enrollment cadence for PALISADE-3 is looking stronger or
32 faster than the first study?

33 <A: Defendant Singh> The question -- the enrollment cadence is on track with
34 what we've guided. I mean look, obviously, the black swan and the pandemic

1 impacted a lot of activity in 1 and 2, although we've been so pleasantly surprised
2 by -- *not really surprised but expected and happy to see, is how normative the*
3 *clinical development environment is now and how we are able to have a lot more*
4 *predictability on the things that caused fits and starts in prior studies during the*
pandemic, especially PALISADE-1. So I can tell you that we're comfortable with
the cadence and we're on track.

5 <A: Defendant Prince> I think that captures it. *The one thing I should have*
6 *mentioned before was the -- there's just a reminder that we have 2 public*
7 *speaking challenges, right? So a key part of this study is the screen out in -- at*
8 *visit 2 and the first public speaking challenge of those subjects who don't have*
9 *a high enough anxiety level to really show improvement. It's one of the things*
10 *that differentiates our study.* And it's not inclusion/exclusion, but it's a key piece
of making sure that we have the right subjects moving forward to the
randomization portion of the study. And those rates, those are critical for study
execution. Those rates have been similar to what we observed in PALISADE-1
and PALISADE 2.

11 (Emphasis added).

12 November 7, 2024

13 29. On November 7, 2024, Vistagen published a press release announcing the
14 Company's second quarter 2025 financial results and corporate update. As part of the press
15 release, Defendant Singh, stated, in relevant part:

16 We are actively recruiting for both our PALISADE-3 and PALISADE-4 Phase 3
17 trials and remain primarily focused on execution. Our broad and diverse
18 neuroscience pipeline is based on our novel, non-systemic, neurocircuitry-focused
19 approaches to treating multiple challenging disorders in high-prevalence markets
20 with inadequate current treatment options. As we head into 2025, we expect data
21 from multiple Phase 3 clinical trials in social anxiety disorder and further
advancement of our non-systemic pherine product candidates in Phase 2 programs
for treatment of major depressive disorder and hormone-free treatment of
menopausal hot flashes, each with potential to set a new standard of care.

22 30. During the question-and-answer portion of the same day earnings call, Defendants
23 commented on the PALISADE-3 trial enrollment, stating, in pertinent part:

24 <Q: Julian Pino – Stifel, Nicolaus & Co. – Analyst> Just wondering if you could
25 provide a little bit of color on the pace of enrollment so far. What are you hearing
26 from investigators about the demand in enrolling in the study? And I was
27 wondering if these parallel studies share trial sites or anything else that you could
28 share about the sites that you've chosen for each study?

1 <A: Defendant Singh> So there's tremendous excitement across the PIs and the
2 site staff that we've been able now to bring together for PALISADE-3 and
3 PALISADE-4, as you can imagine, on the other side of the PALISADE-2 success.
4 We've got 16 sites now that are activated for PALISADE-3 and another -- and a
5 dozen for PALISADE-4.

6 ***So the color I can give you is, again, we -- this is a very important indication.
7 It's very clear throughout the research community and a lot of these sites, of
8 course, have psychiatrists that have been treating patients for a very long time,
9 and they just haven't seen anything new in a very long time,*** let alone something
10 for the acute treatment of social anxiety disorder, which is so important with this
11 disorder is enabling people to engage and not have fear of engaging in the things
12 that stress them in their life, that create anxiety and opportunity costs in their life
13 because they're self-isolating or withholding from engaging.

14 * * *

15 ***We've really enhanced surveillance with our owned assets as well as augmenting
16 that with what we've got as resources from the CRO. So there's a lot of intense
17 training. There's very close surveillance and adherence to the protocols, which
18 is very important, obviously, to control variability. So I think overall, we're
19 happy with how things are going.***

20 (Emphasis added).

21 February 13, 2025

22 31. On February 13, 2025, Vistagen issued a press release announcing the Company's
23 third quarter 2025 financial results and corporate update. As part of the press release, Defendant
24 Singh, stated, in relevant part:

25 We had a very productive quarter, with both PALISADE-3 and PALISADE-4
26 advancing towards expected top-line results later this year....As always, we
27 remain optimistic about the potential of our product candidates to transform
28 standards of care and address multiple significant unmet needs. We continue to
believe that 2025 has the potential to be a monumental year, between multiple
anticipated data readouts for fasedienol in acute treatment of social anxiety
disorder and further advancement of additional pherine product candidates for
treatment of major depressive disorder and menopausal hot flashes.

32. During the question-and-answer portion of the same day earnings call, Defendants
reiterated enhancements made to the execution of the PALISADE-3 trial as well as timeline for
expected data in 2025, stating, in pertinent part:

1 <Q: Matthew Barcus – Jefferies LLC – Equity Analyst> And then I guess, is there
2 anything that keeps you up at night in terms of what more could be done on these
3 studies in terms of execution?

4 <A: Defendant Singh> Interesting question. No, it doesn't keep me up at night
5 because of the enhancements and the team that we've got executing on these
6 studies, especially surveillance associated with rigorous adherence to the protocol.
7 These are all very important, execution-related initiatives that we've got in place,
8 reduced reliance on CRO surveillance, expansion of our internal team, and just the
9 way that we've been seeing the conduct of the studies with rigorous training even
10 upfront of any enrollment at any of the sites. It's just actually been significantly
11 different than what we've seen in the past in a very positive way.

12 <A: Defendant Prince> It is a very interesting question. And actually, to your
13 point, we have more visibility into what's happening with these studies than we
14 did before running PALISADE-1 and 2 in the pandemic and with the
15 enhancements that we've put in place. And so if anything, I would say it's easier
16 to sleep at night now than it was back then without COVID in place, with masks
17 down, with the review that we have of subject's eligibility, making sure that scales
18 are administered properly, making sure that the rigorous public speaking challenge
19 script is followed to the T, and then having the ability to do quick interaction and
20 retraining with sites if they start to deviate from that protocol. So we feel like we're
21 giving these studies the best chance we could at success with those changes.

22 June 2, 2025

23 33. On June 2, 2025, Vistagen published a press release updating the timeline for its
24 ongoing PALISADE-3 Phase 3 program. As part of the release, Defendant Singh stated, in
25 relevant part:

26 We are very encouraged by the progress of our PALISADE-3 trial, which remains
27 on track for a topline readout in the fourth quarter of this year, and our
28 PALISADE-4 trial, for which we expect topline results in the first half of 2026.
Patient and physician enthusiasm for our PALISADE trials continues to be strong,
and we remain focused on meticulous patient recruitment. With social anxiety
affecting millions and rising, we are energized by fasedienol's potential to meet
the clear and growing unmet need and bring meaningful relief to patients, all while
delivering long-term value to shareholders.

29 June 17, 2025

30 34. On June 17, 2025, Vistagen issued a press release announcing the Company's
31 fiscal year 2025 financial results and corporate update. The release stated in pertinent part:

- The U.S. registration-directed PALISADE Program evaluating intranasal fasedienol for the acute treatment of SAD continues to progress. The PALISADE-3 Phase 3 trial remains on track for expected topline data in the fourth quarter of this year. Topline results for the PALISADE-4 Phase 3 trial are expected in the first half of 2026.
- Vistagen believes either PALISADE-3 or PALISADE-4, if successful, together with the positive results from PALISADE-2 reported in the second half of 2023, may establish substantial evidence of the effectiveness of fasedienol in support of a potential fasedienol New Drug Application (NDA) submission to the U.S. FDA for the acute treatment of SAD.

35. On the same day earnings call, Defendant Singh remained confident in delivering top line data from the PALISADE-3 trial in the fourth quarter, stating, in relevant part:

Our PALISADE-3 trial is on track for a top line data readout in the fourth quarter of this year, and we anticipate top line results from PALISADE-4 in the first half of 2026. The enthusiasm of patients and physicians participating in the PALISADE Program continues to be very strong and we remain committed to a rigorous operational execution. If successful, we believe either PALISADE-3 or PALISADE-4, in combination with the positive results from PALISADE-2, could provide the substantial evidence of effectiveness needed to support a new drug application for Fasedienol and its potential to be the first FDA-approved acute treatment for SAD.

* * *

At Vistagen, we welcome the conversations with the FDA, as always about policies that speed up in innovation and make drug development more efficient and affordable and most importantly, improve patient outcomes. Overall, we are energized by the potential of all 5 of our clinical stage pherine product candidates. And with our primary focus on delivering top line data from PALISADE-3 in the fourth quarter of this year, doing so has the near-term potential to transform lives and produce remarkable shareholder value.

36. During the question-and-answer portion of the earnings call, Defendant Singh reiterated the enhancements made to the execution of the PALISADE-3 trial to improve the subject selection and the study execution efficiency, stating, in pertinent part:

<Q: Julian Pino – Stifel, Nicolaus & Co. – Analyst> You alluded to changes with FDA leadership and there's been reports of turnover of staff and medical review teams. I guess in your interactions with the agency, have you noticed any changes or anything that's worth highlighting to sell-side and investors?

<A: Defendant Singh> So back to the PALISADE-4, I think overall, we -- as I think we've talked to you and Paul about in the past and others, the enhancements that we brought to the table related to PALISADE-3, PALISADE-4 from lessons

1 learned and improvements that could be implemented to limit variability, to
2 enhance subject selection, to improve study execution efficiency, those kinds of
3 things, in addition to the mask, obviously coming off and eliminating some of the
4 COVID-related disorders, we really have been focused on very stringent subject
5 eligibility requirements. And some of the original projections that we had were
6 based on observations from PALISADE-2 and the recruitment rates in those
7 studies, which steadily increase through the end of the study, especially when the
8 world got a little bit more normal at the end of PALISADE-2.

9 And the impact of those positive enhancements that we made to PALISADE-3 and
10 4 wasn't really fully understood at the beginning but it's now very apparent and
11 screening visits have continued to increase. And the more stringent subject
12 eligibility requirements and secondary subject eligibility review that we integrated
13 with developing our own internal team in addition to increasing training and
14 remediation. So bottom line, we've been very, very picky in the way that the study
15 can be executed, the stringent inclusion/exclusion criteria, all in an effort to, of
16 course, replicate the success from PALISADE-2.

17 So I think we've got a pretty good rhythm now and we've been able to eliminate
18 subjects who we think may be less likely to demonstrate a benefit through that
19 more rigorous eligibility criteria that we've applied and the secondary review of
20 subject eligibility and site conduct that's ongoing and very specific. So overall, all
21 that together has caused a little bit of an adjustment in timing, but we think that
22 benefits the overall potential outcome of the study.

23 * * *

24 <Q: Lin Tsai – Jefferies LLC – Equity Analyst> And then earlier speaking of
25 variability back in the successful PALISADE-2 study, I think the placebo arm
26 showed a SUDS reduction of 8 points absolute basis. Would you expect that to be
27 the same case for PALISADE-3 and 4? Or with these more enhanced controls
28 could the placebo be lower?

<A: Defendant Singh> Well, what we've certainly done, Andrew, is intended to
design PALISADE-3 and 4 in a manner to replicate the success we saw in
PALISADE-2. Where that actually lands, we'll have to see how the cards flip but
everything that we've done has been intended to limit variability. In any way, we
can conceive of it after taking a look at PALISADE-1 and PALISADE-2 studies,
which were the first two studies, as you know, with this design and this endpoint
for the acute treatment of SAD. So a lot has been learned and the rigor matters,
and so we'll see. The idea, obviously, is to increased visibility into all aspects of
the study and its execution to ensure the highest impossible potential to reduce
variability. So hopefully, that falls in the direction that we saw things land with
PALISADE-2.

<Q: Lin Tsai – Jefferies LLC – Equity Analyst> nd then my last question is in
terms of site conduct and as well as your overall surveillance, are you making sure
these PIs are disqualifying patients appropriately when these patients are taking

1 their SUDS tests? And are you looking at these SUDS rating somehow for each
2 patient to make sure all time points make sense with the scoring?

3 <A: Defendant Singh> Well, the last question, again, whether it makes sense, they
4 are what they are, in terms of the scoring. But what I can tell you in the first hand,
5 I mean, the whole purpose of what we did majorly differently with PALISADE-3
6 and 4 was to develop and have internally what we call our secondary eligibility
7 review team. This is a team, that internal Vistagen team, not a CRO team or a
8 third-party team, but an internal team that consists of very experienced
9 psychometricians who review eligibility of each subject, and they listen to
10 screening assessments as well as each public speaking challenge to ensure in the
11 proper execution.

12 So we think, again, that those kinds of enhancements -- and those are some of the
13 things that take a little bit more time, especially with obviously a hyper-focus on
14 rater training upfront, across all the endpoints, not just the SUDS, but the CGI-I
15 and the PGIC so that you have confidence that the study is being run the way it
16 should be run and that we've done everything that we can through all the
17 experience we've gained through the execution of two studies already to enhance
18 the potential for success.

19 August 7, 2025

20 37. On August 7, 2025, Vistagen issued a press release announcing the Company's
21 fiscal year 2026 first quarter financial results and corporate update. As part of the release
22 Defendant Singh, stated, in relevant part:

23 We had another productive quarter, advancing key programs across our pipeline.
24 Our lead program, fasedienol, for acute treatment of social anxiety disorder,
25 continues to progress, with topline results from our PALISADE-3 Phase 3 trial
26 anticipated later this year, and topline results from our PALISADE-4 Phase 3 trial
27 expected in the first half of 2026. With no FDA-approved acute treatment, we
28 remain optimistic about fasedienol's potential to impact the lives of over 30
million U.S. adults affected by social anxiety disorder.

38. During the question-and-answer portion of the same day earnings call, Defendants
were asked about differences in the PALISADE-3 baseline SUDS score from previous trials,
stating, in pertinent part:

<Q: Lin Tsai – Jefferies LLC – Equity Analyst> And finally, do you envision
PALISADE-3 baseline SUDS score to be any different from the baseline SUDS
in PALISADE 1 and 2? And can you remind us what they were as well?

1 <A: Defendant Prince> Yes, as to 2, I have to look at that. I don't have that off the
2 top of my head, but we would expect them to be similar in terms of those numbers
3 because we have similar inclusion criteria, the post-speaking challenge is set up
4 identically. We would expect it to be the same.

4 <A: Defendant Singh> So it was different. In PAL-2 was 1 minute -- at least 1
5 minute in order to move. Because remember, again, as I think we've talked about,
6 enrollment is different in this study design versus randomization. So it's those that
7 advanced to the visit 3 second speech that are included in the data set. Those are
8 the ones who are randomized. So they have to be sufficiently stressed in the first
9 speech in order to qualify for randomization, and that's set at the 2 minutes at least
10 at 75, more than a little uncomfortable, at least 2 minutes of the 5 minutes during
11 that first speech.

9 <A: Defendant Prince> And Shawn, I would just add to that, we expect baseline
10 to be in that similar range of roughly 80, 85, somewhere in there per SUDS at
11 baseline.

11 <A: Defendant Singh> Yes. Good point. But what we have seen, of course, is the
12 more severely affected and chronically affected someone is with the disorder, and
13 we do a lot upfront to assess that eligibility -- very strict eligibility criteria even
14 before someone signs an ICF, there's rigorous assessment clinically. And then as
15 they move through the eligibility criteria that we've enhanced a bit in PALISADE-
16 3 and 4 are making a difference, we think, to make sure we ensure that we've got
17 a sufficiently suitable population that ultimately gets randomized. So that's been
18 consistent across the objectives from PALISADE-2, 3 and 4.

17 November 3, 2025

18 39. On November 3, 2025, Vistagen issued a press release announcing completion of
19 its PALISADE-3 Phase 3 public speaking challenge study. As part of the release, Defendant
20 Singh, stated, in pertinent part:

21 The completion of the PALISADE-3 Phase 3 public speaking challenge study
22 marks an important milestone for Vistagen. As we advance toward our expected
23 topline results later this quarter, we remain encouraged by fasedienol's potential
24 to become the first and only acute treatment for the more than 30 million people
25 living with social anxiety disorder. We are grateful to the individuals who
26 participated in this study, as well as the clinical investigators, site staff, and our
27 contract research organization for their commitment and collaboration.

26 In August 2023, Vistagen reported positive results from its randomized, double-
27 blind, placebo-controlled PALISADE-2 Phase 3 trial of fasedienol for the acute
28 treatment of social anxiety disorder. The PALISADE-3 trial, and concurrent
PALISADE-4 Phase 3 trial, involve the same public speaking challenge study
design and primary efficacy endpoint as PALISADE-2, with certain protocol and

1 operational enhancements related to site training, surveillance, and subject
2 selection.

3 November 13, 2025

4 40. On November 13, 2025, Vistagen issued a press release reporting second quarter
5 2026 financial results and corporate update. As part of the press release, Defendant Singh, stated,
6 in pertinent part:

7 As we conclude the second quarter of our fiscal year, we are encouraged
8 by our progress and remain confident in the path ahead. We are on track to
9 report topline data from the randomized portion of our PALISADE-
10 3 Phase 3 trial of fasedienol for the acute treatment of social anxiety
11 disorder this quarter, followed by the randomized portion of our
12 PALISADE-4 Phase 3 trial in 2026. We have built strong momentum
13 toward the primary goal of our PALISADE program, developing what we
14 hope could be the first FDA-approved acute treatment of social anxiety
15 disorder for the 30 million adults living with this serious and potentially
16 life-threatening condition.

17 41. During the question-and-answer portion of the same day earnings call, Defendants
18 commented on the PALISADE-3 trial including patient screen fails and FDA filing stating, in
19 relevant part:

20 <Q: Andrew Tsai – Jefferies LLC – Equity Analyst> And then last question is
21 from what you can tell, what have been the top reasons why patients screen failed
22 in PALISADE-3? And are the top reasons different from what you saw in
23 PALISADE-2?

24 <A: Defendant Singh> So we can unpack that later. But what I can tell you,
25 Andrew, is the reason that we made enhancements to the PALISADE-3 and 4
26 studies, again, was to make sure that there's very high-quality assessment for
27 subject eligibility. And as a result of that, we had our own teams involved here
28 with our teams for subject eligibility review. We had other enhancements into the
execution of the study, of course, throughout the duration of the study.

So I think we've seen generally what we've expected to see and as we've modeled
forward for not only screen fail, but also attrition rates throughout the course from
enrollment through randomization through the end of the study. So I think we're
comfortable with what we've typically seen and maybe more to come on that later.
The important piece of the puzzle is -- yes, one more thing is obviously the
important piece of the puzzle is that we got to the last patient class visit with the
full complement that we had modeled for purposes of the studies. We've noted

1 before, our end target was 236. So last patient class visit reflects our original
2 thought.

3 <Q: Unknown Analyst> I guess for us, assuming one of PALISADE-3 or
4 PALISADE-4 works, is there anything else gating registration -- gating filing? Is
there anything else that you need to complete before then? How soon can you file?

5 <A: Defendant Singh> So as you know, as we move closer toward completion of
6 the Phase III development program, we always plan to interact with the agency.
7 But we've said this before, obviously, it's the pivotal program data, it's a repeat
8 dose study. It's the open-label data from our long-term safety study, a human factor
9 study, the typical preclinical safety-related studies, reprotox and carc, all those are
10 aspects that we expect to have wrapped up upfront, of course, of an NDA package.
11 So -- and we'll, of course, be meeting with the FDA as we get closer to make sure
that we're in line with what's necessary regarding a submission package. So we
estimate currently, and if everything goes according to plan that we've been
executing on, we could see an NDA submission if PALISADE-3 is positive
sometime around the middle of '26.

12 <Q: Myles Robert Minter – William Blair & Co. – Analyst> And then second is
13 just, I think in late October, you updated clinicaltrials.gov. You terminated a site
14 in Arkansas and Kansas. I'm just curious whether that was because you've
15 completed enrollment and you didn't need those sites anymore or just because of
your site vigilance and you're going to see these sites in person? Was it something
performance related that you terminated those sites?

16 <A: Defendant Prince> As we've gone through the course of these studies for both
17 PAL-3, PAL-4, it's a constant evaluation of fit with sites. And so we've had a few
18 sites that, for whatever reason with regard to their ability to enroll the appropriate
19 patients, whether it was their recruitment programs or other reasons, just they were
not able to enroll. And so at some point, it makes sense to terminate those sites.
There's been 1 or 2 like that.

20 And then also beyond that, as we -- to your point, as we get towards the end of the
21 study, we definitely take a wind-down approach for a soft landing for the study to
22 make sure it's well controlled. We're controlling variability and then making sure
23 that we will be able to get from that end of study last patient out to top line results
efficiently in the time line that Shawn mentioned. So for us, it's kind of course of
business as we've gone through the process of the studies.

24 42. The above statements in Paragraphs 20 to 41 were false and/or materially
25 misleading. Defendants created the false impression that fasedienol's positive results achieved in
26 the previous PALISADE-2 trial, in addition to notable enhancements and operational changes
27 made to the execution of the PALISADE-3 clinical trial supported a strong likelihood of Phase 3
28

1 success and positioned it as a confirmatory study. In truth, Defendants had knowingly or
2 recklessly omitted the risk of failure inherent in public speaking challenge-based Social Anxiety
3 Disorder clinical trials. Specifically, Defendants were aware from its own Phase 2 experience and
4 published clinical research that public speaking challenge endpoints often exhibit elevated
5 placebo responses, site variability and measurement noise, yet continued to tout modifications
6 made to the Phase 3 trial and presenting PALISADE-3 as likely to succeed.

8 **The Truth Emerges**

9 *December 17, 2025*

10 43. On December 17, 2025, Vistagen issued a press release reporting that its
11 PALISADE-3 Phase 3 study did not demonstrate a statistically significant improvement on the
12 primary endpoint of change on the SUDS. The press release further stated, in pertinent part:

13
14 The trial did not achieve its primary endpoint, as measured by the least squares
15 (LS) mean change from baseline on the Subjective Units of Distress Scale (SUDS)
16 score for fasedienol (13.6 +/-1.54 standard error, SE) compared with placebo (14.0
17 +/-1.51 SE), a LS mean difference of 0.4 (p = not significant). There was no
treatment difference between fasedienol and placebo for the secondary endpoints.
The favorable safety data of fasedienol were consistent with previous clinical
trials.

18 44. As part of the press release, Defendant Singh added:

19
20 We are disappointed by the unexpected results of this public speaking challenge
21 trial, which are inconsistent with positive outcomes observed in Phase 2 and our
22 PALISADE-2 Phase 3 study. We are thoroughly reviewing the results of the study,
evaluating the potential impact of the results on our ongoing studies and plan to
seek feedback from the FDA.

23 45. The aforementioned press releases and statements made by the Individual
24 Defendant are in direct contrast to statements they made during the press releases and associated
25 earnings calls held on June 11, 2024, August 13, 2024, November 7, 2024, February 13, 2025,
26 June 17, 2025, August 7, 2025, and November 13, 2025. During the earnings calls and related
27 statements, Vistagen's executives continually touted the progress of the Company's PALISADE-
28

1 3 Phase 3 study of intranasal fasedienol, including the “notable enhancements” and “operational
2 changes” made to the execution of the trial to position PALISADE-3 as a confirmatory study. In
3 actuality, Defendants had knowingly or recklessly omitted the risk of failure inherent in public
4 speaking challenge-based Social Anxiety Disorder clinical trials. Specifically, Defendants were
5 aware from its own Phase 2 experience and published clinical research that public speaking
6 challenge endpoints often exhibit elevated placebo responses, site variability and measurement
7 noise, yet continued to tout modifications made to the Phase 3 trial and presenting PALISADE-3
8 as likely to succeed.
9

10 46. Investors and analysts reacted immediately to Vistagen’s revelation. The price of
11 Vistagen’s common stock declined dramatically from a closing market of \$4.36 per share on
12 December 16, 2025 to \$0.86 per share on December 17, 2025, a decline of more than 80%.
13

14 47. A number of well-known analysts who had been following Vistagen downgraded
15 their shares in response to Vistagen’s disclosures. For example, Jefferies analyst noted “[a] pattern
16 is emerging in that fasedienol’s efficacy (absolute) remains fairly consistent across studies, just
17 that placebo remains quite variable. However, PAL-3’s outcome raises a question of where the
18 true placebo rate should trend, especially given the limited historical precedents for the novel
19 SUDS endpoint.”
20

21 48. Similarly, William Blair analyst downgraded its shares viewing the Phase 3
22 PALISADE-3 miss as “disappointing” and noting that “we are now uncertain if fasedienol is an
23 active agent for the acute treatment of SAD.”
24

25 **Additional Scienter Allegations**

26 49. During the Class Period, Defendants acted with scienter in that they knew, should
27 have known, or otherwise were deliberately reckless in not knowing that the public statements
28 disseminated on behalf of Vistagen were materially false and misleading at the time they were

1 made. Defendants had actual knowledge of, or access to, non-public information concerning the
2 inherent risks associated with Vistagen’s PALISADE-3 Phase 3 public speaking challenge
3 clinical trial design, including its own PALISADE-2 trial results as well as regular internal
4 meetings and updates with principal investigators on enrollment quality, site performance and
5 operational metrics.

6
7 50. Despite such knowledge, Defendants repeatedly conveyed to investors that its
8 PALISADE-3 Phase 3 study was on track to produce positive results. similar to the prior. In fact,
9 Defendants knew about the risks associated with public speaking challenge trial design from its
10 previous PALISADE-2 study, specifically that endpoints often exhibit elevated placebo responses
11 and that patient selection criteria and trial sites vary enough to materially affect results.

12
13 51. Defendants’ knowledge concerning the faulty design of the trial and extraordinary
14 risks related to the endpoints is also evident from the fact that they made “notable enhancements”
15 and “operational changes” to the execution of the trial in an effort to correct and/or avoid the
16 issues that presented internally (but were not disclosed publicly).

17 **Loss Causation and Economic Loss**

18 52. During the Class Period, as detailed herein, Vistagen and the Defendants made
19 materially false and misleading statements and engaged in a scheme to deceive the market and a
20 course of conduct that artificially inflated the price of Vistagen’s common stock and operated as
21 a fraud or deceit on Class Period purchasers of Vistagen’s common stock by materially misleading
22 the investing public. Later, when Vistagen and Defendants’ prior misrepresentations and
23 fraudulent conduct became apparent to the market, the price of Vistagen’s common stock
24 materially declined, as the prior artificial inflation came out of the price over time. As a result of
25 their purchases of Vistagen’s common stock during the Class Period, Plaintiff and other members
26 of the Class suffered economic loss, *i.e.*, damages under federal securities laws.
27
28

1 (d) Unexpected material news about Vistagen was reflected in and incorporated into
2 the Company's stock price during the Class Period.

3 56. As a result of the foregoing, the market for Vistagen common stock promptly
4 digested current information regarding the Company from all publicly available sources and
5 reflected such information in Vistagen's stock price. Under these circumstances, all purchasers
6 of Vistagen's common stock during the Class Period suffered similar injury through their
7 purchase of Vistagen's common stock at artificially inflated prices, and a presumption of reliance
8 applies.
9

10 57. Alternatively, reliance need not be proven in this action because the action
11 involves omissions and deficient disclosures. Positive proof of reliance is not a prerequisite to
12 recovery pursuant to ruling of the United States Supreme Court in *Affiliated Ute Citizens of Utah*
13 *v. United States*, 406 U.S. 128 (1972). All that is necessary is that the facts withheld be material
14 in the sense that a reasonable investor might have considered the omitted information important
15 in deciding whether to buy or sell the subject security.
16

17 **No Safe Harbor; Inapplicability of Bespeaks Caution Doctrine**

18 58. The statutory safe harbor provided for forward-looking statements under certain
19 circumstances does not apply to any of the material misrepresentations and omissions alleged in
20 this Complaint. As alleged above, Defendants' liability stems from the fact that they provided
21 investors with materially misleading statements about its financial growth and stability while at
22 the same time omitting then existing material adverse information concerning the Company's
23 advertising practices. Defendants provided the public with information about their operations that
24 failed to account for negative realities concerning their undisclosed conduct.
25

26 59. To the extent certain of the statements alleged to be misleading or inaccurate may
27 be characterized as forward looking, they were not identified as "forward-looking statements"
28

1 can be ascertained only through appropriate discovery, Plaintiff believes that there are hundreds
2 or thousands of members in the proposed Class. Record owners and other members of the Class
3 may be identified from records maintained by Vistagen or its transfer agent and may be notified
4 of the pendency of this action by mail, using the form of notice similar to that customarily used
5 in securities class actions. As of November 12, 2025, there were 39.4 million shares of the
6 Company's common stock outstanding. Upon information and belief, these shares are held by
7 thousands, if not millions, of individuals located throughout the country and possibly the world.
8 Joinder would be highly impracticable.
9

10 63. Plaintiff's claims are typical of the claims of the members of the Class as all
11 members of the Class are similarly affected by Defendants' wrongful conduct in violation of
12 federal law that is complained of herein.
13

14 64. Plaintiff will fairly and adequately protect the interests of the members of the Class
15 and has retained counsel competent and experienced in class and securities litigation. Plaintiff has
16 no interests antagonistic to or in conflict with those of the Class.
17

18 65. Common questions of law and fact exist as to all members of the Class and
19 predominate over any questions solely affecting individual members of the Class. Among the
20 questions of law and fact common to the Class are:

- 21 (a) whether the federal securities laws were violated by Defendants' acts as alleged
22 herein;
- 23 (b) whether statements made by Defendants to the investing public during the Class
24 Period misrepresented material facts about the business, operations and
25 management of Vistagen;
- 26 (c) whether the Individual Defendants caused Vistagen to issue false and misleading
27 financial statements during the Class Period;
28

- 1 (d) whether Defendants acted knowingly or recklessly in issuing false and misleading
2 financial statements;
- 3 (e) whether the prices of Vistagen's common stock during the Class Period were
4 artificially inflated because of the Defendants' conduct complained of herein; and
5
- 6 (f) whether the members of the Class have sustained damages and, if so, what is the
7 proper measure of damages.

8 66. A class action is superior to all other available methods for the fair and efficient
9 adjudication of this controversy since joinder of all members is impracticable. Furthermore, as
10 the damages suffered by individual Class members may be relatively small, the expense and
11 burden of individual litigation make it impossible for members of the Class to individually redress
12 the wrongs done to them. There will be no difficulty in the management of this action as a class
13 action.
14

15 **COUNT I**

16 ***Against All Defendants for Violations of***
17 ***Section 10(b) and Rule 10b-5 Promulgated Thereunder***

18 67. Plaintiff repeats and realleges each and every allegation contained above as if fully
19 set forth herein.

20 68. This Count is asserted against defendants and is based upon Section 10(b) of the
21 Exchange Act, 15 U.S.C. § 78j(b), and Rule 10b-5 promulgated thereunder by the SEC.

22 69. During the Class Period, Defendants engaged in a plan, scheme, conspiracy and
23 course of conduct, pursuant to which they knowingly or recklessly engaged in acts, transactions,
24 practices and courses of business which operated as a fraud and deceit upon. Plaintiff and the
25 other members of the Class; made various untrue statements of material facts and omitted to state
26 material facts necessary in order to make the statements made, in light of the circumstances under
27 which they were made, not misleading; and employed devices, schemes and artifices to defraud
28

1 in connection with the purchase and sale of securities. Such scheme was intended to, and,
2 throughout the Class Period, did: (i) deceive the investing public, including Plaintiff and other
3 Class members, as alleged herein; (ii) artificially inflate and maintain the market price of
4 Vistagen's common stock; and (iii) cause Plaintiff and other members of the Class to purchase or
5 otherwise acquire Vistagen's securities at artificially inflated prices. In furtherance of this
6 unlawful scheme, plan and course of conduct, Defendants, and each of them, took the actions set
7 forth herein.
8

9 70. Pursuant to the above plan, scheme, conspiracy and course of conduct, each of the
10 defendants participated directly or indirectly in the preparation and/or issuance of the quarterly
11 and annual reports, SEC filings, press releases and other statements and documents described
12 above, including statements made to securities analysts and the media that were designed to
13 influence the market for Vistagen's securities. Such reports, filings, releases and statements were
14 materially false and misleading in that they failed to disclose material adverse information and
15 misrepresented the truth about the Company.
16

17 71. By virtue of their positions at the Company, Defendants had actual knowledge of
18 the materially false and misleading statements and material omissions alleged herein and intended
19 thereby to deceive Plaintiff and the other members of the Class, or, in the alternative, Defendants
20 acted with reckless disregard for the truth in that they failed or refused to ascertain and disclose
21 such facts as would reveal the materially false and misleading nature of the statements made,
22 although such facts were readily available to Defendants. Said acts and omissions of defendants
23 were committed willfully or with reckless disregard for the truth. In addition, each defendant
24 knew or recklessly disregarded that material facts were being misrepresented or omitted as
25 described above.
26
27
28

1 72. Information showing that Defendants acted knowingly or with reckless disregard
2 for the truth is peculiarly within defendants' knowledge and control. As the senior manager and/or
3 director of the Company, the Individual Defendant had knowledge of the details of Vistagen's
4 internal affairs.

5 73. The Individual Defendant is liable both directly and indirectly for the wrongs
6 complained of herein. Because of his position of control and authority, the Individual Defendant
7 was able to and did, directly or indirectly, control the content of the statements of the Company.
8 As officer and/or director of a publicly-held company, the Individual Defendant had a duty to
9 disseminate timely, accurate, and truthful information with respect to Vistagen's businesses,
10 operations, future financial condition and future prospects. As a result of the dissemination of the
11 aforementioned false and misleading reports, releases and public statements, the market price of
12 Vistagen's common stock was artificially inflated throughout the Class Period. In ignorance of
13 the adverse facts concerning the Company which were concealed by Defendants, Plaintiff and the
14 other members of the Class purchased or otherwise acquired Vistagen's common stock at
15 artificially inflated prices and relied upon the price of the common stock, the integrity of the
16 market for the common stock and/or upon statements disseminated by Defendants, and were
17 damaged thereby.

18 74. During the Class Period, Vistagen's common stock was traded on an active and
19 efficient market. Plaintiff and the other members of the Class, relying on the materially false and
20 misleading statements described herein, which the Defendants made, issued or caused to be
21 disseminated, or relying upon the integrity of the market, purchased or otherwise acquired shares
22 of Vistagen's common stock at prices artificially inflated by Defendants' wrongful conduct. Had
23 Plaintiff and the other members of the Class known the truth, they would not have purchased or
24 otherwise acquired said common stock, or would not have purchased or otherwise acquired them
25
26
27
28

1 at the inflated prices that were paid. At the time of the purchases and/or acquisitions by Plaintiff
2 and the Class, the true value of Vistagen's common stock was substantially lower than the prices
3 paid by Plaintiff and the other members of the Class. The market price of Vistagen's common
4 stock declined sharply upon public disclosure of the facts alleged herein to the injury of Plaintiff
5 and Class members.

6
7 75. By reason of the conduct alleged herein, Defendants knowingly or recklessly,
8 directly or indirectly, have violated Section 10(b) of the Exchange Act and Rule 10b-5
9 promulgated thereunder.

10 76. As a direct and proximate result of Defendants' wrongful conduct, Plaintiff and
11 the other members of the Class suffered damages in connection with their respective purchases,
12 acquisitions and sales of the Company's common stock during the Class Period, upon the
13 disclosure that the Company had been disseminating misrepresented financial statements to the
14 investing public.
15

16 **COUNT II**

17 ***Against the Individual Defendants*** 18 ***for Violations of Section 20(a) of the Exchange Act***

19 77. Plaintiff repeats and realleges each and every allegation contained in the foregoing
20 paragraphs as if fully set forth herein.

21 78. During the Class Period, the Individual Defendant participated in the operation
22 and management of the Company, and conducted and participated, directly and indirectly, in the
23 conduct of the Company's business affairs. Because of his senior position, he knew the adverse
24 non-public information about Vistagen's misstatements.
25

26 79. As officer and/or director of a publicly owned company, the Individual Defendant
27 had a duty to disseminate accurate and truthful information, and to correct promptly any public
28 statements issued by Vistagen which had become materially false or misleading.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

C. Awarding Plaintiff and the other members of the Class pre-judgment and post-judgment interest, as well as their reasonable attorneys' fees, expert fees and other costs; and

D. Awarding such other and further relief as this Court may deem just and proper.

DEMAND FOR TRIAL BY JURY

Plaintiff hereby demands a trial by jury.

Dated: